Inner Mongolia veterinary biologics maker best known for foot-and-mouth disease vaccines for pigs and cattle.
Inner Mongolia veterinary biologics maker best known for foot-and-mouth disease vaccines for pigs and cattle.
Sells vaccines both to provincial animal-husbandry bureaus that buy for mandatory immunisation programmes and to farms directly, so a government purchase cycle and the size of herds set demand.
In one line: A livestock-vaccine Zoetis, but China-only.
Moat: narrow (regulatory licence, scale). One of a small number of licensed FMD-vaccine producers under China's state biosecurity program.
Headquarters: Hohhot, Inner Mongolia, China · Employees: 1,881
Size Jinyu Bio-Technology (600201.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.93B, the 1203rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.81 on 18 Nov 2026.
Performance Over six months the shares fell 21.3%, against -1.3% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 21.9% over the last twelve months (peer median +8.7%); the operating margin is 9.7% (peer median 20.9%).
Valuation It trades at 59.0× forward earnings against a peer median of 20.0× (2nd most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.5 points below its cost of capital (8.8% WACC).
Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.60B | CN¥1.39B | CN¥1.23B | CN¥1.59B | CN¥1.52B |
| Revenue growth | — | +13% | -22% | +5% | — |
| Gross profit | CN¥997M | CN¥621M | CN¥571M | CN¥882M | CN¥759M |
| EBITDA | n/a | CN¥258M | CN¥251M | CN¥436M | CN¥452M |
| Net income | CN¥165M | CN¥100M | CN¥109M | CN¥284M | CN¥211M |
| Free cash flow | CN¥259M | CN¥222M | CN¥255M | CN¥166M | CN¥190M |
| Capital expenditure | CN¥123M | CN¥121M | CN¥89.7M | CN¥273M | CN¥190M |
| Total debt | CN¥334M | CN¥75.7M | CN¥161M | CN¥218M | CN¥24.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jinyu Bio-Technology 600201.SS | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% |
| Pulike Biological Engineering 603566.SS | $449M | -21% | -9% | 5% | 23.2× | 4.5% |
| Zoetis ZTS | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% |
| Tianjin Ringpu Bio-technology 300119.SZ | $1.11B | -7% | -9% | 11% | 18.1× | 4.9% |
| China Animal Husbandry Industry 600195.SS | $921M | -16% | +1% | 2% | 41.5× | 6.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600201.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.4% | +2.7% | 8th lowest of 21 |
| 6-month return | -21.3% | -1.3% | 5th lowest of 21 |
| Distance from 52-week high | -37.8% | -28.2% | 4th lowest of 21 |
| Revenue growth (TTM) | +21.9% | +8.7% | 3rd highest of 20 |
| Operating margin | 9.7% | 20.9% | 6th lowest of 20 |
| Forward P/E | 59.0× | 20.0× | 2nd most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 23.4% | 1.5% | 2nd most demanding of 13 |
| Growth delivered (Del g) | -2.5% | +12.3% | lowest of 13 |
| Hurdle (Req g minus delivered) | +25.9 pp | -12.1 pp | most demanding of 13 |
| ROIC minus cost of capital | -2.5 pp | +1.6 pp | 6th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| InnoCare Pharma 9969.HK | Hong Kong | $2.01B | -10% | +146% | 35% | 32.2× | -2.0% | +341.1% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |